Clinical trial · Interventional
Stress Reduction in Ovarian Cancer
Stress Reduction During Primary Adjuvant Chemotherapy for Ovarian Cancer
NCT01790789CI-TRIAL-00041754completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the effects of a stress reduction program on the quality of life of ovarian cancer patients during primary adjuvant chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian, Fallopian, and Primary Peritoneal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Attention control | Other | — | UNRESOLVED |
| Daily stress reduction program | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Stress reduction program
- interventionNames
- Behavioral: Daily stress reduction program
- type
- OTHER
- label
- Attention control
- interventionNames
- Other: Attention control
Primary outcomes (1)
- measure
- Fatigue
- timeFrame
- 18 weeks (completion of chemotherapy)
- description
- Fatigue will be measured using the NIH PROMIS Cancer Fatigue survey instrument
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects must have an initial diagnosis of ovarian, fallopian tube or primary peritoneal cancer who completed primary ovarian cancer surgery or 3 cycles of neoadjuvant chemotherapy with interval cytoreductive surgery (ICS). * Final pathology diagnosis of stage I-IV ovarian, fallopian tube or primary peritoneal cancer with plan to receive primary adjuvant chemotherapy or completion of chemotherapy after ICS. * Receive chemotherapy at the University of Wisconsin-Madison. * Subjects must be at least 18 years of age. * English-speaking * Subjects must be able to use audio media, and read and understand the study manual. * ECOG performance status 0-2. * Subjects must have a phone. Exclusion Criteria: * Subjects participating in a meditation practice more than 1 hour per week prior to surgery and/or chemotherapy administration. * Subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer. * Subjects with diagnosis of Chronic Fatigue Syndrome (CFS). * Subjects unable to use audio media due to auditory dysfunction. * Subjects unable to read written English. * Subjects who are prisoners or incarcerated.
References
Publications (0)
Data not yet available
No reference posted for this study.